Investors Focus On Devices, Services In China, But Drug R&D Still Has Some Attraction
This article was originally published in PharmAsia News
Executive Summary
China attracted $1.9 billion in private equity investment in health care-related fields in 2013, making the sector second only to real estate. But investors at a recent forum in Beijing had divergent opinions on whether the smart money should head into developing devices, clinics or new drug R&D.